Figure 2From: Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer Overall Survival. Median overall survival for patients in all cohorts was 10.5 months (95% CI, 4.2 to 22.7)Back to article page